Navigation Links
Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Date:1/3/2008

dies further support continued development of ANA598 as a candidate for use in combination with other agents for the treatment of chronic HCV infection."

In June 2007, Anadys announced the nomination of ANA598 as a clinical development candidate. The selection of ANA598 represented the culmination of a comprehensive structure-based drug design program directed towards NS5B. ANA598 was selected based on an optimized balance of preclinical properties, including intrinsic potency as an NS5B inhibitor, cellular activity in the replicon assay, oral bioavailability and early indicators of safety and tolerability. ANA598 is a low-nanomolar inhibitor of HCV genotype 1a and 1b replicons. It exhibits good in vitro metabolic stability properties and does not significantly inhibit or induce cytochrome P450 enzymes. In vivo, ANA598 was well tolerated in 14-day dose range finding (DRF) animal toxicology studies. At doses corresponding to estimated human doses, 24 hour trough plasma concentrations of ANA598 exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition. The EC95 is the concentration required in vitro to suppress hepatitis C viral RNA levels by 95% in the replicon assay.

ANA598 is currently completing IND enabling activities and an IND submission is targeted for the second quarter of 2008. "After completing the necessary IND enabling studies, we look forward to exploring the potential clinical utility of ANA598," said James Freddo, MD, Anadys' Chief Medical Officer. "Based on the in vitro and in vivo potency, pharmacokinetic and preliminary toxicologic properties of ANA598 demonstrated to date, we believe that this is an exciting new direct antiviral to investigate for the treatment of patients with hepatitis C virus infection."

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
4. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
7. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...USTON, Nov. 6 Cyberonics...ompany will report financial results for the secon...r ending April 30, 2010 on Wednesday, November 18,...conference call to discuss those results on Thursd...al Year 2010 Second Quarter Results Conference Cal...
(Date:11/6/2009)...N DIEGO, Nov. 6 California America...9 as "No Drugs Down the Drain" week for its San Di...aign sponsored by public and private agencies alik...ical pollution in our source water supplies. ,,...omers are encouraged to drop off expired or unwant...
(Date:11/5/2009)...INT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall...T ), a specialty pharmaceutical company focused on...ary products that address important therapeutic ne...it will host a webcast and teleconference with man...sults on Thursday, November 12, 2009, at 5:00 p.m....
Breaking Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Statement From the National Pork Board on Testing of Pigs for H1N1 59692 1Omnicell to Release Third Quarter 2009 Earnings Results on October 22 59690 1Omnicell to Release Third Quarter 2009 Earnings Results on October 22 59690 2Virginia Restaurants Urged to Go Completely Smoke Free After Major Report Finds Smoke Free Laws Prevent Heart Attacks 59687 1Virginia Restaurants Urged to Go Completely Smoke Free After Major Report Finds Smoke Free Laws Prevent Heart Attacks 59687 2Virginia Restaurants Urged to Go Completely Smoke Free After Major Report Finds Smoke Free Laws Prevent Heart Attacks 59687 3
(Date:11/8/2009)...f H.R. 3961 to Secure the Stability of Medicare ,...atement Attributable to: J. James Rohack, M.D., Pr...: http://www.newscom.com/cgi-bin/prnh/20081209/A... House health reform bill, which will help improve... calls for swift passage of H.R. 3961 to secure th...
(Date:11/8/2009)...e of Health Care Reform Bill ,, Critical legi...e for all Americans ,, BALTIMORE, Nov. 7 /PRNe...d States House of Representatives passed critical ...en Medicare for seniors and end discrimination by ...ans out of affordable health coverage. ,, The A...
(Date:11/7/2009)...re-USNewswire/ -- The American Medical Association...for Citizenship and Community Service to Manus C. ...The award recognizes physicians who have gone abov...ke an outstanding public service contribution to t... today during the opening session of the 2009 Inte...
(Date:11/7/2009)...e-USNewswire/ -- Members of the AMA are trying a l...tion rescinding the AMA,s support of HR 3962. ,...ponsible to their PATIENTS, not the leadership of ...for the Association of American Physicians and Sur...r medical groups. ,, "If the AMA leadership ig...
(Date:11/7/2009)...wire-USNewswire/ -- Speaker Nancy Pelosi and Democ...noon following a Democratic Whip meeting with Pres...the Speaker,s opening remarks: ,, "Thank you v...for us to receive the President of the United Stat... our vote and making progress for the American peo...
Breaking Medicine News(10 mins):Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2
...Biotechnologies ( www.epeiusbiotech.com ) today ... Rexin-G, a tumor-targeted anti-cancer agent desig...t have spread throughout the body. While Rexin-G i... I/II studies and a Phase II confirmatory trial in...
...nd Patient Advocacy Efforts , , SAN DIEGO, May 18... announced awards received at the American Thoraci...Diego, Calif. being held this week. The ATS meeti...that, to date, has funded $400,000 in new pulmonar...
...dent of the Pharmaceutical analytics company Eular...l if you are making the wrong marketing decision. ...on the latest techniques, strategies and analysis,...1 Northumberland Avenue, Trafalgar Square. London,...
...nown effect of healthcare reform create unpreceden...an, Inc., one of the premier global consulting and...al medical spending for its "typical American fami...ighest since 2006. , , The Milliman Medical Index...
...e Therapeutics, Inc. announced today that it has...h the addition of Pratik Multani, M.D., M.S., as V...than a decade of clinical development experience, ...or therapeutic purposes. SCMs can potentially be ...
... promise for better protection against flu , ...ade up of virus-like particles (VLPs) could provid...lu viruses than conventional vaccines, researchers...nes, according to research presented May 18 at the...
Other Medicine News:Health News:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 2Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 2Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 3Health News:MEDIA ALERT - Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London 2Health News:Milliman Indicates 2009 Medical Cost for 'American family of four' Exceeds $16,700 Based on 7.4% Cost Increase 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 3Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 4Health News:New Methods Could Speed Production of Flu Vaccines 2
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
Medicine Products: